• Viking Therapeutics will present two posters on obesity drug candidate VK2735 at ObesityWeek, November 14-17, 2026, in Washington, D.C.
• The November 14 presentation will detail baseline characteristics from Phase 3 VANQUISH-2 in adults with overweight and type 2 diabetes.
• A November 15 poster will examine subcutaneous VK2735's impact on obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611090705PR_NEWS_USPR_____LA92229) on November 09, 2026, and is solely responsible for the information contained therein.